

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

### **VOLUNTARY ANNOUNCEMENT**

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”) on a voluntary basis. Reference is made to the announcements (the “**Announcements**”) of the Company dated January 29, 2024, February 4, 2024 and March 7, 2024 in relation to the Draft Bill that has been introduced in the U.S. Congress. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company has noted that a meeting in relation to, among others, a revised version of the Draft Bill (H.R.8333) was held by the U.S. House Committee on Oversight and Accountability on May 15, 2024. Such revised version of the Draft Bill differs from the previous version in several respects, including, among others, the removal of alleged finding pertaining to the Company’s CEO and a proposed “grandfather” clause with transition period through January 1, 2032. It is also noted that the revised version of the Draft Bill includes the Company’s name in the proposed definition of the term “biotechnology company of concern”, which the Company firmly believes is a preemptive and unjustified designation without due process.

As a global biologics CRDMO platform, the Company does not have a human genomics business, nor does it collect human genomic data in any of its businesses around the world. The Company reiterates that it has not, does not and will not pose a security risk to the United States or any other countries.

The contents of the revised Draft Bill remain subject to further review and modification as it moves through the legislative process. The Company is closely monitoring this process and remains committed to supporting its customers globally and to operating with the highest standards of compliance and in accordance with the applicable laws and regulations of all jurisdictions where it has business operations.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, May 17, 2024

*As at the date of this announcement, the board of directors of the Company comprises Dr. Zhisheng Chen as executive Director; Dr. Ge Li, Dr. Weichang Zhou, Dr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.*

\* *For identification purpose only*